García-Fernández et al. (2016) found that the presentation of TP53 mutations in cfDNA might be used as a biomarker of tumor recurrence in patients with transplanted HCC. Furthermore, Rui-Hua Xu et al. (2017) constructed a prognostic prediction model based on methylation alterations in cfDNA to effectively predict prognosis and survival (p < 0.001), which was highly correlated with tumor burden, treatment response, and stage. The gene discussed is TP53; the disease is hepatocellular carcinoma.